Printer Friendly

MOLECULAR BIOSYSTEMS INC. ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH ABBOTT LABORATORIES

 SAN DIEGO, March 3 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) ("MBI") announced today that its wholly owned subsidiary Syngene Inc. has entered into an exclusive option agreement with Abbott Laboratories. The agreement gives Abbott the right to acquire worldwide rights to Syngene's proprietary diagnostic probe technology for the in vitro diagnosis of infectious diseases and cancer. Syngene's operations were discontinued as of the end of September 1992.
 The agreement allows Abbott to evaluate the probe technology before exercising its option to acquire worldwide rights to Syngene's patent estate covering the technology. Financial details of the transaction were not disclosed.
 The technology is used for the in vitro diagnosis of infectious diseases and cancer. The probes are short sequences of nucleotides, which are basic building blocks of DNA (deoxyribonucleic acid). These sequences are designed to bind only with complementary sequences of the genetic material of disease-causing organisms. This binding may be observed through detection of a "label" placed in the probe sequence. If such binding is observed in samples taken from patients, the physician may positively determine whether the disease- causing organism is present. Syngene's probe technology differs from other non-radioactive DNA probes in that its patented process permits placement of the "label" at any point in the sequence of nucleotides, resulting in greater stability, sensitivity and specificity.
 Molecular Biosystems Inc., based in San Diego, is a leader in the development of contrast agents for medical imaging, including ultrasound, MRI and CT. MBI's shares are listed on the New York Stock Exchange under the symbol "MB."
 -0- 3/3/93
 /CONTACT: Beth Field Wallace, manager of investor relations of Molecular Biosystems, 619-452-0681, ext. 2212/
 (MB)


CO: Molecular Biosystems Inc.; Abbott Laboratories ST: California IN: MTC SU:

JL-LS -- SD001 -- 2310 03/03/93 09:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 3, 1993
Words:294
Previous Article:BANK OF AMERICA-MANAGED FIRST FUNDS AND FIRST CASH FUNDS WILL BECOME PACIFIC HORIZON FUNDS
Next Article:ALDUS ANNOUNCES FETCH TRADE-UP OFFER
Topics:


Related Articles
Perkin-Elmer and Roche Molecular Systems Announce Cross-Licensing Agreement with Amersham to Expand Use of Automated DNA Sequencing Technology
Quidel Corporation Completes Acquisition of Metra Biosystems; Quidel Expands Product Line Into Osteoporosis Diagnostics.
Vysis Receives FDA Clearance for UroVysion Bladder Recurrence Cancer Test.
Ambion Signs Armored RNA(R) Licensing Agreement With Celera Diagnostics.
Abbott Laboratories Announces Agreement with Atria Genetics for HLA Tissue Typing Tests.
Research and Markets - Market for Clinical Molecular Diagnostics Testing Equipment and Supplies in the Clinical Hospital Market Analysed.
Abbott Laboratories and artus GmBH Expand Agreement for Molecular Diagnostics Tests.
Abbott Laboratories Announces Agreement With Atria Genetics for HLA Tissue Typing Tests; - HLA Tests Enable Labs to Better Identify Appropriate Bone...
Abbott Laboratories and artus Introduce Automated Diagnostic Tests for SARS And Other Infectious Diseases; - Three New Automated PCR Tests on ABI...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters